PT  - JOURNAL ARTICLE
AU  - Nguyen, Thuy Phuong
AU  - Stirling, Christine
AU  - Kitsos, Gemma
AU  - Jose, Kim
AU  - Nichols, Linda
AU  - Chandra, Ronil V.
AU  - Rehman, Sabah
AU  - Smith, Karen
AU  - Mosley, Ian
AU  - Lai, Leon
AU  - Asadi, Hamed
AU  - Dubey, Arvind
AU  - Froelich, Jens
AU  - Thrift, Amanda
AU  - Gall, Seana
TI  - Advancing convergent mixed methods design using the Diamond Approach for clinical multiple case studies: an example using data on time to treatment in aneurysmal subarachnoid haemorrhage
AID  - 10.1101/2021.09.08.21263308
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.08.21263308
4099  - http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263308.short
4100  - http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263308.full
AB  - Using a new approach to the analysis and synthesis of a clinically focused mixed-methods multiple case study of aneurysmal subarachnoid haemorrhage (aSAH), we explored barriers and facilitators to timely treatment. In this paper we provide guidance for the multiple steps of analysis and synthesis of qualitative and quantitative data from across and within 27 case studies. Results showed that median (IQR) time to treatment was 15.1 (9.0, 24.1) hours. Only 37% of cases had treatment within 12-hours of onset. Early recognition of aSAH, good coordination, and availability of resources for treatment were main facilitators for treatment within 12 hours from onset. Lack of recognition of aSAH at onset and lack of resources for immediate in-hospital treatment were major barriers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Health and Medical Research Council [grant number 1143155].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by Monash University (HREC/44916/MonH-2018-155101(v1)), Monash Health (RES-18-0000-648A) and University of Tasmania (H0017834).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.